Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Apr 19, 2018 6:26pm
131 Views
Post# 27914340

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New presentation is up on the company website

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New presentation is up on the company website Around half the HIV+ people in the US dont get any sort of medical intervention. Their number, 400,000 to 600,0000, far out weighs the number of MDR patient under treatment (25,000). Untreated patients likely have out-of-control virus levels, falling CD4 cell counts and are headed for full blown AIDS just like many MDR patients. It's these people that make up the bulk of the HIV deaths. They likely dont need Torgarzo just access to a regular ART regimen. 
So hopefully Trogarzo does impact the death rate in the MDR cohort but thats only a small number of HIV deaths, it wont significantly impact the overall death rate unfortunately.


TOM2008 wrote: In the United States, 6,721 people died from HIV and AIDS in 2014. HIV remains a significant cause of death for certain populations. In 2014, it was the 8th leading cause of death for those aged 25-34 and 9th for those aged 35-44.
www.cdc.gov/hiv/basics/statistics.html

At least more than 6721 patients will need Trogarzo help  ever year to avoid  Facing death threats .

2014  death (any reasons)with hiv 16,254 

2014 death(any reasons) at HIV/AIDS stage 3 (CD4+T  < 200 copies/mlor AIDS) 13,129

www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2016-vol-28.pdf


Bullboard Posts